Chronic Pain Clinical Trial
Official title:
Self-Administered Skills-Based Virtual Reality Intervention for Chronic Pain: A Randomized Controlled Pilot Study
Chronic pain management is optimized with a multidisciplinary biopsychosocial treatment
approach. However, patients have limited access to comprehensive care that includes
behavioral medicine for chronic pain. Virtual reality (VR) is an immersive technology and
emerging digital behavioral pain therapeutic with analgesic efficacy for acute pain. No
scientific literature was found for skills-based VR behavioral programs for chronic pain
populations.
The primary goal of this study was to evaluate the feasibility of a self-administered VR
program that included content and skills informed by evidence-based cognitive behavioral
treatment for chronic pain. The secondary goal was to determine the preliminary efficacy of
the VR program in terms of average pain intensity and pain-related interference with
activity, stress, mood, and sleep, and its impact on pain-related cognition and
self-efficacy. The tertiary goal was to conduct a randomized controlled trial to compare the
VR treatment to an audio-only treatment; this comparison isolated the immersive effects of
the skills-based VR program, thereby informing potential mechanisms of effect.
This randomized controlled clinical trial was conducted between March and May of 2019.
Participants were recruited through online advertisements on Facebook and The Mighty, a
digital health community. Screening included a 2-item measure to assess for anhedonia and
depressive symptoms experienced over the past two weeks. Potential participants were excluded
from the study if they endorsed experiencing either depression or anhedonia nearly every day,
and the other more than half the days. Eligible study participants were English-fluent adults
18-65 years of age, with either self-reported chronic low back pain without radicular
symptoms and/or fibromyalgia pain of > 6 months duration,[29] and with average pain intensity
> 4 (using the 11-point Numerical Rating Scale; 0=no pain, 10=worst pain imaginable) over the
past month at screening. Exclusionary criteria included cognitive impairment, medical
condition predisposing one to nausea or dizziness, hypersensitivity to flashing light or
motion, absence of stereoscopic vision, severe hearing impairment, facial/head injury that
would cause discomfort with VR use, cancer-related pain, severe depression, active
suicidality, and previous use of Pain Care VR.
After informed consent was obtained study participants were randomized one-to-one using a
REDCAP Cloud random number generator and allocated to treatment group. All study procedures
were completed remotely and no in-person visits were required. Study participants were not
blinded to treatment group assignment due to the obvious nature of the mode of delivery of
their assigned treatment. Participant compensation was prorated based on the number of
surveys completed; participants received up to $30 in the form of an Amazon.com e-gift card
following completion of the final study survey. The study was approved by the Western
Institutional Review Board (Puyallup, WA).
Data collection consisted of electronically collected patient-reported measures and objective
use data collected from the VR devices and audio access logs.
In accordance with the Initiative on Methods, Measurement, and Pain Assessment in Clinical
Trials (IMMPACT) recommendations, multiple methods evaluated the importance of change in
outcome measures across four recommended domains: pain intensity, health-related quality of
life as defined by physical functioning, and ratings of overall Improvement.
Both treatment groups received the same didactic content delivered in distinct formats (VR
vs. Audio). Treatment content consisted of a variety of sessions to support participants in
learning cognitive and behavioral self-management skills based on evidence-based CBT
principles and skills, biofeedback and mindfulness strategies used in pain management.
The 21-day program consisted of 4-8 treatment sessions from each content category with the
duration of session length ranging from 1-15 minutes. Each treatment session was indexed as
complete if participants initiated the experience. Participants were allowed to replay
completed sessions.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01659073 -
Using Perfusion MRI to Measure the Dynamic Changes in Neural Activation Associated With Caloric Vestibular Stimulation
|
N/A | |
| Recruiting |
NCT05914311 -
Use of Dermabond in Mitigation of Spinal Cord Stimulation (SCS) Trial Lead Migration
|
N/A | |
| Recruiting |
NCT05422456 -
The Turkish Version of Functional Disability Inventory
|
||
| Enrolling by invitation |
NCT05422443 -
The Turkish Version of Pain Coping Questionnaire
|
||
| Completed |
NCT05057988 -
Virtual Empowered Relief for Chronic Pain
|
N/A | |
| Completed |
NCT04385030 -
Neurostimulation and Mirror Therapy in Traumatic Brachial Plexus Injury
|
N/A | |
| Recruiting |
NCT06206252 -
Can Medical Cannabis Affect Opioid Use?
|
||
| Completed |
NCT05103319 -
Simultaneous Application of Ketamine and Lidocaine During an Ambulatory Infusion Therapy as a Treatment Option in Refractory Chronic Pain Conditions
|
||
| Completed |
NCT03687762 -
Back on Track to Healthy Living Study
|
N/A | |
| Completed |
NCT04171336 -
Animal-assisted Therapy for Children and Adolescents With Chronic Pain
|
N/A | |
| Completed |
NCT03179475 -
Targin® for Chronic Pain Management in Patients With Spinal Cord Injury
|
Phase 4 | |
| Completed |
NCT03418129 -
Neuromodulatory Treatments for Pain Management in TBI
|
N/A | |
| Completed |
NCT03268551 -
MEMO-Medical Marijuana and Opioids Study
|
||
| Recruiting |
NCT06060028 -
The Power of Touch. Non-Invasive C-Tactile Stimulation for Chronic Osteoarthritis Pain
|
N/A | |
| Recruiting |
NCT06204627 -
TDCS* and Laterality Trainnning in Patients With Chronic Neck Pain
|
N/A | |
| Completed |
NCT05496205 -
A SAD Study to Evaluate the Safety, Tolerability and PK/PD of iN1011-N17 in Healthy Volunteers
|
Phase 1 | |
| Completed |
NCT00983385 -
Evaluation of Effectiveness and Tolerability of Tapentadol Hydrochloride in Subjects With Severe Chronic Low Back Pain Taking Either WHO Step I or Step II Analgesics or no Regular Analgesics
|
Phase 3 | |
| Recruiting |
NCT05118204 -
Randomized Trial of Buprenorphine Microdose Inductions During Hospitalization
|
Phase 4 | |
| Terminated |
NCT03538444 -
Repetitive Transcranial Magnetic Stimulation for Opiate Use Disorder
|
N/A | |
| Not yet recruiting |
NCT05812703 -
Biometrics and Self-reported Health Changes in Adults Receiving Behavioral Treatments for Chronic Pain
|